Mannosyltransferase-6 Deficiency

Mannosyltransferase-6 deficiency is a very rare, inherited condition that affects how the body builds sugar chains on proteins (a process called N-linked glycosylation). In healthy cells, an enzyme encoded by the ALG12 gene adds a specific sugar (mannose) in an alpha-1,6 linkage to a growing sugar chain inside the endoplasmic reticulum. This step is essential to make fully formed glycoproteins that help nearly every organ work well. When the ALG12 enzyme does not work properly, the sugar chain stays incomplete. As a result, many proteins are under-glycosylated and do not function normally. This multi-system condition is also called ALG12-congenital disorder of glycosylation (ALG12-CDG, formerly CDG-Ig). Signs usually begin in infancy and can include feeding difficulties, poor growth, low muscle tone, developmental delay, frequent infections (often due to low antibodies), unusual facial features, problems with blood clotting, male genital differences, and sometimes heart, bone, hearing, or seizure problems. Diagnosis relies on transferrin glycoform testing and genetic testing of ALG12. There is no approved disease-specific therapy yet; care is supportive and targeted to symptoms. PubMed+3PubMed+3MedlinePlus+3

Mannosyltransferase 6 deficiency” usually refers to ALG6-congenital disorder of glycosylation (ALG6-CDG). The name can be confusing: the ALG6 gene actually makes an enzyme that is a glucosyltransferase, not a mannosyltransferase. This enzyme sits in the cell’s endoplasmic reticulum and puts the first glucose onto a growing sugar chain that will later be attached to many proteins (this process is N-linked glycosylation). When ALG6 does not work well because of gene variants, the sugar chain is incomplete. Many proteins across the body then fold poorly or do not reach their normal destination. Because these proteins are used everywhere, many organs can be affected, especially the brain, liver, muscles, eyes, hormones, and blood-clotting system. NCBI+1

---

Other names

• ALG6-CDG

• Congenital disorder of glycosylation type Ic (CDG-Ic) — older name

• Glucosyltransferase I deficiency (ALG6) — describes the enzyme step

• ALG6-related CDG (ALG6-related congenital disorder of glycosylation) MedlinePlus

---

What is happening inside the body

Cells build a sugar tree (called an oligosaccharide) on a lipid “scaffold” and then transfer it to new proteins. ALG6’s job is to add the first glucose to that tree. Without that first glucose, the tree is built incorrectly. Proteins that need this tree do not fold properly, are not shipped correctly, and some are destroyed. This causes wide-ranging problems: developmental delay, weak muscles, seizures, feeding problems, hormone and clotting issues, and sometimes eye or liver disease. NCBI+1

---

Types

There is one genetic disease (ALG6-CDG), but doctors sometimes group patients by clinical pattern to guide care:

1. Classic early-infancy neurologic form. Babies have low muscle tone, delayed milestones, and may have seizures. Feeding problems and poor growth are common. Orpha

2. Neuro-gastro-hepatic form. Neurologic signs plus feeding problems, failure to thrive, and intermittent liver-enzyme rises, especially during infections. NCBI

3. Endocrine-pubertal form (mainly in girls). Neurologic features can be mild; some females have delayed or absent puberty (hypergonadotropic hypogonadism). MalaCards

4. Epilepsy-predominant form. Seizures are the leading issue; some series describe a recognizable phenotype. Wiley Online Library+1

5. Milder/adolescent presentations. Less common, but reported, often recognized after genetic testing of neurodevelopmental symptoms. cdghub.com

Note: In ALG6-CDG, some “classic CDG signs” like inverted nipples, abnormal fat distribution, or cerebellar hypoplasia are less frequent than in PMM2-CDG (the most common CDG). PubMed+1

---

Causes

The root cause is always pathogenic variants in the ALG6 gene. Below are 20 concrete “cause/risk/context” items that explain how and why disease happens or looks different across people:

1. Loss-of-function variants in ALG6 (missense, nonsense, frameshift, splice). These reduce or abolish glucosyltransferase I activity. MedlinePlus

2. Common missense variant p.A333V (c.998C>T). Reported often and linked to founder effects in some populations. Nature+1

3. Other recurrent variants (e.g., p.I299del, p.G227E, p.P354L) described in case series. Wiley Online Library+2PubMed+2

4. Compound heterozygosity (two different pathogenic variants, one on each copy). PMC

5. Homozygosity for a pathogenic allele (more likely with parental consanguinity). SpringerLink

6. Large gene deletions of ALG6 (rare, but reported). biochemia-medica.com

7. Variants that impair ER localization or stability of the ALG6 protein, lowering effective enzyme levels. (Mechanistic principle summarized from gene function.) NCBI

8. Variants that reduce substrate binding (poor use of dolichyl-phosphate-glucose), lowering first-glucose transfer. genome.ucsc.edu

9. Temperature or cellular stress sensitivity of some mutant enzymes, worsening function during illness (infections can unmask liver abnormalities). NCBI

10. ER quality-control overload because mis-glucosylated glycoproteins misfold and are degraded. (Mechanistic consequence of defective first-glucose step.) PMC

11. Downstream protein hypoglycosylation in the brain → neurodevelopmental symptoms. PMC

12. Hypoglycosylated clotting factors → coagulopathy features (e.g., low antithrombin, factor XI issues). NCBI

13. Hormone-receptor hypoglycosylation → endocrine issues (e.g., delayed/absent puberty in some females). MalaCards

14. Vision pathway protein hypoglycosylation → strabismus/retinal issues in a subset. MalaCards

15. Gastro-hepatic involvement from misprocessing of secreted proteins → feeding difficulty, enzyme flares. Orpha

16. Genetic background (modifiers) that can soften or worsen the phenotype. (Inferred principle across CDG; phenotypic variability widely noted.) Frontiers

17. Founder effects in certain regions increasing the frequency of specific ALG6 variants. Nature

18. Limited residual enzyme activity (some variants are “hypomorphic”), producing milder courses. PubMed

19. Age-related emergence of features (e.g., puberty-related endocrine signs appear later). MalaCards

20. No environmental cause: this is inherited, autosomal recessive—parents are typically healthy carriers. (Inheritance for ALG6-CDG.) MedlinePlus

---

Common symptoms

1. Developmental delay. Children reach milestones later because many brain proteins are under-glycosylated. MedlinePlus

2. Low muscle tone (hypotonia). Muscles feel floppy; impacts feeding and motor skills. Orpha

3. Seizures/epilepsy. Misglycosylated neuronal proteins raise seizure risk; some patients have epilepsy-predominant courses. Wiley Online Library

4. Poor feeding and failure to thrive. Weak suck, reflux, and inefficient swallowing are common in infancy. Orpha

5. Ataxia/poor coordination. The balance system is affected, leading to unsteady movements. NCBI

6. Strabismus (crossed/ misaligned eyes). Eye muscles and visual pathways may be affected. MalaCards

7. Vision problems (e.g., retinal issues). Some patients have progressive eye findings. MalaCards

8. Intermittent liver enzyme rises, often during intercurrent infections. NCBI

9. Bleeding/clotting abnormalities. Changes in antithrombin or factor XI can appear on labs; some patients bruise easily or bleed longer. NCBI

10. Learning difficulties and speech delay. School-age challenges vary widely. cdghub.com

11. Behavior or psychiatric concerns (reported in case experiences; care must be individualized). PubMed

12. Poor head control in infancy. Early sign of hypotonia. Orpha

13. Endocrine issues in females (delayed or absent puberty). Metabolic Support UK

14. Failure to gain weight/short stature relative to peers. MalaCards

15. Variable facial features (subtle compared with some other CDGs). The “classic” CDG stigmata (inverted nipples, abnormal fat) are less common here. PubMed+1

---

Diagnostic tests

A) Physical examination

1. General pediatric/neurologic exam. Checks tone, reflexes, strength, development, and coordination; establishes the baseline and tracks progress. Orpha

2. Growth and nutrition assessment. Weight/length/head size trends identify failure to thrive and guide feeding support. MalaCards

3. Eye alignment and visual behavior check. Screens for strabismus and visual dysfunction that need ophthalmology referral. MalaCards

4. Bleeding and bruising history/skin exam. Looks for signs suggestive of clotting factor issues. NCBI

5. Pubertal staging (especially girls). Detects delayed or absent puberty needing endocrine testing. Metabolic Support UK

B) Bedside/“manual” clinical tests

6. Developmental screening tools (e.g., Bayley, Denver). Translate observations into measurable scores to plan therapies. (General pediatric practice in neurodevelopmental disorders.)

7. Cerebellar coordination tests (finger-to-nose, heel-to-shin). Identify ataxia that matches parent reports.

8. Gait and balance assessment (tandem, Romberg). Characterizes motor control for physio plans.

9. Swallow/suck evaluation by speech-language therapist. Guides safe feeding plans.

10. Ophthalmologic bedside tests (cover–uncover, acuity screening). Trigger detailed eye work-up if abnormal.
    (These bedside tests complement, but do not replace, lab/imaging/genetic tests.)

C) Laboratory and pathological tests

11. Serum transferrin isoform analysis (isoelectric focusing—the classic first-line screen for N-glycosylation defects). A type I pattern points to an assembly/transfer defect like ALG6-CDG; confirm with genetics. PMC+1

12. Alternative transferrin methods (HPLC, capillary electrophoresis, or mass spectrometry) where available; results parallel IEF. Frontiers+1

13. Apolipoprotein C-III (ApoC-III) isoform analysis. Helps when a type II pattern is suspected and to evaluate O-glycosylation; complements transferrin testing. Annals of Translational Medicine

14. Coagulation panel (PT, aPTT) plus antithrombin and factor XI levels. Detects the characteristic coagulopathy pattern in some patients. NCBI

15. Liver enzymes (ALT/AST), albumin, and bilirubin to look for hepatopathy or infection-triggered flares. NCBI

16. Endocrine labs (FSH, LH, estradiol/testosterone, thyroid tests) when puberty or growth is abnormal. Metabolic Support UK

17. Genetic testing — targeted ALG6 sequencing, CDG gene panel, or exome/genome. Confirms the diagnosis and identifies the specific variants (e.g., p.A333V, p.I299del, others). MedlinePlus+1

D) Electrodiagnostic tests

18. EEG for seizure evaluation and medication planning. (Epilepsy is common in ALG6-CDG.) Wiley Online Library

19. Nerve conduction/EMG when peripheral neuropathy is suspected (less common, but considered if there is weakness or sensory loss). (General CDG neuromuscular approach.) Frontiers

20. Visual evoked potentials (VEP) if visual pathway dysfunction is suspected to guide vision supports. (General neuro-ophthalmic practice in metabolic/ genetic disorders.)

E) Imaging studies (additional key tools)

• Brain MRI to look for structural correlates of hypotonia/ataxia or seizures; in ALG6-CDG, classic CDG signs such as major cerebellar hypoplasia are less frequent than in PMM2-CDG, but MRI is still useful for care planning. PubMed

• Abdominal ultrasound if liver is enlarged or labs are abnormal. (General hepatology practice.)

• Ophthalmic imaging (OCT/fundus) when vision problems are reported. (General ophthalmic care.)

Non-pharmacological treatments (therapies & others)

These measures support function, nutrition, development, and safety. Many should start early and run in parallel. Always individualize with your care team.

1. Feeding therapy (SLP/OT-led): Helps with suck–swallow–breathe coordination, texture progression, and safe swallowing to reduce choking and improve growth. Purpose: better nutrition and fewer chest infections. Mechanism: skill training, postural adjustments, pacing.

2. High-calorie diet planning (dietitian): Adds density (oils, powders) and schedules frequent small feeds. Purpose: prevent failure to thrive. Mechanism: increases caloric intake to match higher energy needs from illness and therapies.

3. Reflux and aspiration precautions: Upright feeds, thickened liquids (if advised), slow flow nipples. Purpose: reduce vomiting and aspiration pneumonia. Mechanism: mechanical reduction in backflow and mis-direction to airway.

4. Tube feeding (NG/PEG) support: If oral intake is unsafe or inadequate. Purpose: reliable calories, meds, and fluids. Mechanism: bypasses oral phase; can be temporary or long-term.

5. Physiotherapy (gross motor): Low-to-moderate intensity stretches, trunk control, and gait training. Purpose: improve tone, posture, and mobility. Mechanism: neuro-motor learning, muscle strengthening, contracture prevention.

6. Occupational therapy (fine motor/ADLs): Hand skills, adaptive utensils, seating, and daily living strategies. Purpose: independence and caregiver relief. Mechanism: graded practice and environmental modification.

7. Speech-language therapy (communication): Early language stimulation; AAC if speech is delayed. Purpose: functional communication. Mechanism: alternative pathways (symbols, devices) to express needs.

8. Developmental/early-intervention programs: Coordinated plans across therapies and school supports. Purpose: maximize neurodevelopment. Mechanism: enriched, repetitive learning during neuroplastic windows.

9. Hearing support (audiology): Early screening; hearing aids or cochlear implant candidacy if loss is significant. Purpose: enable language and social development. Mechanism: amplifies or bypasses damaged pathways.

10. Vision care (ophthalmology/optometry): Correct refractive errors, manage strabismus. Purpose: optimize input for learning. Mechanism: lenses, patching, or surgical referral.

11. Orthotics & positioning: AFOs, seating systems, sleep positioning. Purpose: prevent deformity, improve energy efficiency. Mechanism: external support to joints and posture.

12. Bone health program: Weight-bearing activities; calcium/vitamin D guidance; fracture prevention. Purpose: reduce osteopenia risk from low mobility. Mechanism: mechanical loading + nutrition.

13. Respiratory hygiene: Chest physiotherapy when indicated; airway clearance during infections. Purpose: fewer complications. Mechanism: mobilizes secretions.

14. Infection-risk reduction: Hand hygiene, crowd control during outbreaks, prompt fever plans. Purpose: fewer serious infections in hypogammaglobulinemia. Mechanism: exposure reduction and early response.

15. Seizure safety plan: Supervision during bathing/swimming; rescue-medication training for caregivers. Purpose: reduce injury and delayed treatment. Mechanism: preparedness.

16. Coagulation precautions: If labs show clotting defects, avoid high-risk activities; medical alert ID. Purpose: mitigate bleeding/thrombosis risks. Mechanism: risk awareness and rapid care.

17. Cardiac monitoring routines: Scheduled echocardiograms if cardiomyopathy suspected; activity guidance. Purpose: detect and manage early heart involvement. Mechanism: surveillance and graded exercise.

18. Dental/oral care plan: Early dentist visits; fluoride and feeding-position tips to limit caries from frequent feeds. Purpose: maintain oral health. Mechanism: preventive dentistry.

19. Care coordination & genetics counseling: Family planning, carrier testing, and linkage to CDG networks. Purpose: informed decisions and support. Mechanism: education on autosomal recessive inheritance.

20. Psychosocial support: Parent training, respite care, patient groups. Purpose: reduce caregiver stress and improve adherence. Mechanism: social and mental-health scaffolding. (Core disease background informing these measures: MedlinePlus+1)

---

Drug treatments

There is no approved curative drug for ALG12-CDG. Medicines below are used to treat specific problems such as infections, seizures, reflux, heart issues, and coagulation abnormalities. Doses are typical examples; clinicians individualize to age, weight, kidneys/liver, interactions, and local guidelines.

1. Intravenous immunoglobulin (IVIG): for low IgG with recurrent infections. Class: pooled antibodies. Example dose: 0.4–0.8 g/kg every 3–4 weeks. Purpose: reduce infections. Mechanism: passive immunity. Side effects: headache, fever, thrombo-risk, aseptic meningitis (rare). cdghub.com

2. Amoxicillin-clavulanate (or appropriate antibiotics): for bacterial infections per culture/local guidance. Class: beta-lactam + inhibitor. Dose: per weight. Purpose: treat infections. Side effects: diarrhea, rash.

3. Azithromycin (when indicated): alternative for certain infections. Class: macrolide. Purpose: treat atypical/respiratory infections. Side effects: GI upset, QT risk.

4. Levetiracetam: first-line for seizures. Class: antiepileptic. Typical pediatric start: 10 mg/kg twice daily titrated. Mechanism: SV2A modulation. Side effects: irritability, somnolence.

5. Valproate (if suited): broad-spectrum antiepileptic. Mechanism: GABA increase; sodium channel effects. Key caution: liver/pancreas toxicity; teratogenic; monitor labs.

6. Clobazam or benzodiazepine rescue (diazepam, midazolam): for breakthrough seizures. Purpose: abort prolonged seizures. Side effects: sedation, respiratory depression risk.

7. Baclofen (if spasticity emerges later): Class: GABA_B agonist. Dose: start low, titrate. Side effects: sedation, weakness.

8. Omeprazole (or another PPI): for reflux/esophagitis. Purpose: reduce acid, improve comfort and weight gain. Side effects: diarrhea, low Mg (long-term).

9. Domperidone/metoclopramide (where allowed): pro-motility for gastric emptying; use cautiously. Side effects: QT risk (domperidone), extrapyramidal (metoclopramide).

10. Ondansetron: for vomiting during illness/feeds. Class: 5-HT3 antagonist. Side effects: constipation, QT risk.

11. Polyethylene glycol: for constipation related to low tone/diet. Mechanism: osmotic laxative. Side effects: bloating.

12. Enalapril (if cardiomyopathy): Class: ACE inhibitor. Purpose: afterload reduction. Side effects: cough, kidney considerations.

13. Carvedilol (cardiomyopathy): Class: beta-blocker. Purpose: improve ventricular function. Side effects: bradycardia, hypotension.

14. Furosemide (heart failure or fluid overload): Class: loop diuretic. Side effects: electrolyte loss, dehydration.

15. Vitamin K (if prolonged INR from factor deficiency): Class: cofactor. Purpose: support clotting factor carboxylation. Side effects: rare hypersensitivity (IV).

16. Antithrombin concentrate or plasma products (if specific factor levels are very low and bleeding/thrombosis risk is high): Purpose: correct deficits peri-procedurally; specialist decision.

17. Testosterone (boys with hypogonadism) or pediatric endocrinology-guided hormone therapy: Purpose: induce puberty or treat micropenis when indicated. Caution: specialist dosing/monitoring.

18. Cholecalciferol (Vitamin D3): for low levels and bone health, usually with calcium. Typical dose: per deficiency protocol. Side effects: hypercalcemia if excessive.

19. Albuterol (salbutamol) inhaler during respiratory illnesses with wheeze. Class: beta-2 agonist. Side effects: tremor, tachycardia.

20. Paracetamol/acetaminophen for pain/fever support; avoid NSAIDs if bleeding risk exists. Mechanism: central COX modulation. Caution: liver dosing limits.

(These choices reflect supportive management of features known in ALG12-CDG; there is no enzyme replacement or approved substrate therapy for ALG12 at present.) cdghub.com+1

---

Dietary / molecular supplements

Supplements do not correct the core glycosylation step in ALG12-CDG, unlike mannose therapy which helps a different CDG subtype (MPI-CDG). Discuss each item with your clinician.

1. Energy-dense formulas or modular add-ons (MCT oil, carbohydrate powders): improve caloric intake.

2. Vitamin D3 + calcium: bone support in low mobility.

3. Iron (if iron-deficiency anemia is present): only after confirming labs.

4. Zinc: may aid appetite and immune function if deficient.

5. Coenzyme Q10: mitochondrial support is theoretical; mixed evidence.

6. L-carnitine: may help fatty-acid transport in select kids with low levels.

7. Omega-3 fatty acids: general anti-inflammatory and cardiometabolic support.

8. Multivitamin with minerals: fills gaps in picky eaters or tube-fed patients.

9. Probiotics (selected strains): may reduce antibiotic-associated diarrhea; avoid in severely immunocompromised states without advice.

10. Sodium-bicarbonate/citrate (only if metabolic acidosis is documented): corrects acid–base imbalance per specialist guidance.

(No current evidence shows these reverse ALG12-CDG; they are supportive.) MedlinePlus

---

Immunity booster / regenerative / stem-cell” topics

There are no proven regenerative or stem-cell drugs for ALG12-CDG in clinical care today. The items below reflect research concepts or general immune support, not standard therapy.

1. Up-to-date vaccinations: strongest “immunity booster” we have; protects against severe infections.

2. IVIG (listed above): passive immune support when IgG is low; evidence-based for hypogammaglobulinemia.

3. Gene therapy (research stage): in-principle fix by supplying a working ALG12; no approved trials for routine care yet.

4. mRNA/enzyme delivery concepts (preclinical): attempts to supplement missing function transiently; not available clinically for ALG12.

5. iPSC-based disease modeling: helps scientists study ALG12 defects and screen drugs; not a treatment for patients today.

6. Hematopoietic stem cell transplant (HSCT): not established for ALG12-CDG; only considered in other conditions when immune or marrow defects are primary. At present, HSCT is not a recommended therapy for ALG12-CDG. cdghub.com

---

Surgeries/procedures

1. Gastrostomy tube (PEG) placement: for unsafe or insufficient oral feeding; ensures nutrition, hydration, and medication delivery.

2. Anti-reflux surgery (fundoplication): rarely, for severe, refractory reflux with aspiration despite maximal medical therapy.

3. Orthopedic procedures: to correct contractures, hip subluxation, or scoliosis that limit function or cause pain.

4. Genital/urogenital surgery (e.g., hypospadias repair, orchiopexy): addresses male genital anomalies to improve function and hygiene.

5. Cochlear implantation: for severe sensorineural hearing loss when hearing aids are inadequate.

---

Prevention strategies

1. Genetic counseling for parents and family (autosomal recessive inheritance; 25% recurrence risk in each pregnancy). MedlinePlus

2. Newborn/infant monitoring plan (growth, feeding, tone) to act early.

3. Vaccinations on schedule, including influenza and others recommended locally.

4. Hand hygiene + sick-day plans to lower infection risk.

5. Early therapy enrollment (PT/OT/SLP) to prevent secondary complications.

6. Fall and seizure-proofing the home (bath safety, supervision, helmet if recommended).

7. Regular dental care to prevent caries from frequent feeds or reflux.

8. Bone-health routines (weight-bearing, vitamin D adequacy).

9. Cardiac and coagulation surveillance per specialist to prevent silent progression.

10. Written emergency sheet listing diagnosis, risks (e.g., coagulation issues), meds, and clinician contacts.

---

When to see a doctor urgently

• Any fever ≥38.0°C in infants, or fever with lethargy, breathing difficulty, or dehydration signs.

• Seizures, especially first seizure, a prolonged seizure (>5 minutes), or repeated seizures.

• Breathing problems, bluish lips, or repeated choking.

• Signs of bleeding (easy bruising, nosebleeds that won’t stop, black stools) or signs of clot (swollen painful limb, sudden chest pain).

• Poor feeding or weight loss, frequent vomiting, or concerns with the tube site.

• New heart symptoms (sweating with feeds, poor exercise tolerance).

• Any sudden change in alertness, strength, or behavior.

---

What to eat and what to avoid

What to eat/do:

• Energy-dense, balanced meals: add healthy fats (oils, nut butters if safe), protein, and complex carbs.

• Frequent, small feeds if large meals are hard.

• Adequate fluids and fiber to reduce constipation.

• Vitamin D and calcium sufficiency for bones (diet and/or supplements if advised).

• Safe swallowing textures recommended by the therapist.

What to limit/avoid:

• Hard-to-chew or easy-to-choke foods if oral-motor skills are delayed.

• Acidic/spicy foods late in the day if reflux is a problem.

• Unpasteurized or undercooked foods during times of high infection risk.

• Alcohol and smoking exposure in the home environment.

• Self-starting supplements without approval—some interact with seizure or heart medicines.

---

Frequently asked questions

1. Is ALG12-CDG the same as “mannosyltransferase-6 deficiency”?
   Yes. ALG12 encodes the alpha-1,6-mannosyltransferase needed for N-glycan assembly; its deficiency is called ALG12-CDG (CDG-Ig). PubMed+1

2. How common is it?
   Very rare; only a small number of patients have been reported worldwide. cdghub.com

3. What are the most typical symptoms?
   Feeding difficulty, poor growth, low muscle tone, developmental delay, low antibody levels with recurrent infections, coagulation problems, and sometimes skeletal, genital, heart, or seizure issues. MedlinePlus+1

4. How is it diagnosed?
   By transferrin glycoform analysis (showing under-glycosylation) and confirmatory genetic testing of ALG12. MedlinePlus

5. Is there a cure?
   No approved disease-specific treatment yet; care is supportive and focuses on each complication. MedlinePlus

6. Does oral mannose help?
   No. Mannose therapy benefits MPI-CDG, a different subtype, not ALG12-CDG. (Your team can explain why.) MedlinePlus

7. Why do infections happen more often?
   Many patients have low IgG (antibodies). Some need IVIG to reduce infections. cdghub.com

8. Can it affect blood clotting?
   Yes. Some have abnormal coagulation tests; management is individualized, especially before surgery. cdghub.com

9. What about the heart?
   A few patients develop cardiomyopathy; cardiology follow-up is advised if suspected. cdghub.com

10. Will my child walk or talk?
    Outcomes vary widely—from mild to severe. Early therapies and supports help each child reach their personal best. Wiley Online Library

11. Is hearing loss possible?
    Yes, sensorineural hearing loss is reported in some cases. Early audiology checks are important. fcdgc.rarediseasesnetwork.org

12. Is it inherited?
    Yes. Autosomal recessive: each parent usually carries one non-working copy; the child inherits both. MedlinePlus

13. Should relatives get tested?
    Carrier testing and prenatal options can be discussed with a genetic counselor. MedlinePlus

14. Are clinical trials available?
    Trials for ALG12-CDG are limited; families can watch rare-disease networks and CDG foundations for updates. fcdgc.rarediseasesnetwork.org

15. What is the most important daily action for families?
    Keep care plans (feeding, seizure, infection, coagulation) updated, attend scheduled therapies, and connect with specialized centers and support groups. cdghub.com

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.